Selective angiotensin-(1-7) antagonist
CAT No: 10-101-277
CAS No:159432-28-7
Synonyms/Alias:159432-28-7;A 779;A-779;(D-Ala7)-Angiotensin I/II (1-7);CHEMBL4578721;(2R,5S,8S,11S,14S,17S,20S)-5-((1H-imidazol-4-yl)methyl)-20-amino-8-((S)-sec-butyl)-17-(3-guanidinopropyl)-11-(4-hydroxybenzyl)-14-isopropyl-2-methyl-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazadocosanedioic acid;(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(1R)-1-carboxyethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid;Ang(1-7) D-Ala7;BDBM85554;HY-P0216;BDBM50514583;AKOS027470317;H-Asp-Arg-Val-Tyr-Ile-His-D-Ala-OH;DA-60644;MS-31620;A3281;A-779?;D88558;(2R,5S,8S,11S,14S,17S,20S)-5-((1H-imidazol-4-yl)methyl)-20-amino-8-sec-butyl-17-(3-guanidinopropyl)-11-(4-hydroxybenzyl)-14-isopropyl-2-methyl-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazadocosane-1,22-dioic acid;
(D-Ala7)-Angiotensin I/II (1-7) is a synthetic peptide analog derived from the native angiotensin (1-7) sequence, distinguished by the substitution of D-alanine at the seventh residue. This structural modification imparts enhanced metabolic stability and resistance to enzymatic degradation, making the compound a valuable tool for probing the biological functions of the angiotensin peptide family. As a research reagent, (D-Ala7)-Angiotensin I/II (1-7) is commonly utilized to investigate the intricate mechanisms of the renin-angiotensin system (RAS), particularly in the context of peptide-receptor interactions, signal transduction, and physiological regulation. Its selective activity profile and resistance to rapid inactivation enable detailed studies of angiotensin (1-7) pathways in various experimental models.
Receptor pharmacology: The peptide serves as an essential probe for characterizing the Mas receptor, a G protein-coupled receptor implicated in mediating the effects of angiotensin (1-7). By employing this analog in receptor binding assays and functional studies, researchers can delineate the specificity, affinity, and signaling mechanisms associated with Mas receptor activation. The substitution of D-alanine at the C-terminus allows for the differentiation between receptor-mediated effects and those arising from peptide degradation products, facilitating a more precise understanding of angiotensin (1-7) pharmacodynamics.
Signal transduction research: (D-Ala7)-Angiotensin I/II (1-7) is widely used to dissect intracellular signaling cascades initiated by angiotensin peptides. Its stability in biological matrices makes it particularly suitable for experiments that require sustained receptor engagement, such as studies of second messenger systems, kinase activation, and gene expression modulation. The compound enables researchers to elucidate downstream pathways regulated by the Mas receptor, supporting investigations into cellular processes such as proliferation, apoptosis, and differentiation.
Enzymatic processing studies: The D-alanine modification confers resistance to enzymatic cleavage by peptidases such as angiotensin-converting enzyme (ACE) and neprilysin. This property makes the analog a valuable standard in assays examining the metabolic fate of angiotensin peptides and the activity of peptidases involved in RAS regulation. By comparing the degradation rates of native and modified peptides, scientists can assess the contribution of specific enzymes to peptide turnover and stability, advancing the understanding of peptide metabolism in physiological and pathological contexts.
Peptide structure-activity relationship (SAR) analysis: The unique configuration of (D-Ala7)-Angiotensin I/II (1-7) supports its use in SAR studies aimed at identifying critical determinants of receptor binding and biological activity. Incorporation of D-amino acids enables systematic evaluation of stereochemical requirements for Mas receptor activation, providing insights that inform the design of novel peptide analogs with tailored pharmacological profiles. Such research is instrumental in advancing peptide engineering and the development of selective RAS modulators for experimental applications.
In vivo and ex vivo modeling: The enhanced stability of this peptide analog makes it an ideal candidate for use in animal models and tissue preparations where prolonged activity is required to study angiotensin (1-7)-mediated physiological responses. Its resistance to rapid degradation allows for more consistent and interpretable results in experiments investigating cardiovascular, renal, or neuroendocrine functions regulated by the RAS. Through these applications, the compound supports the generation of robust preclinical data and deepens the mechanistic understanding of angiotensin peptide biology.
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More